Investment Summary

Craneware PLC is a leading provider of value cycle management software solutions to the US healthcare market, helping hospitals, health systems and provider organisations improve their financial performance, operational efficiency and clinical outcomes. The combination of structural Demand for healthcare cost management, growing adoption of cloud-based analytics solutions, strong customer retention and a track record of disciplined operational execution supports an attractive long-term investment proposition. With Revenue/">Recurring Revenue dominant, expanding margins and meaningful cross-sell opportunities following the Sentry Data Systems Acquisition, the company is well positioned to deliver sustained value creation. We rate the shares a Buy.

Business Overview

Craneware is headquartered in Edinburgh, Scotland, and is listed on the London Stock Exchange AIM market. The company serves the US healthcare provider market, with customers including hospitals, health systems, integrated delivery networks and clinical service providers. The product portfolio addresses what the company terms the 'value cycle', spanning charge management and pricing, contract management, revenue integrity, value-based care, drug acquisition cost management through the 340B Drug Pricing Program and broader operational analytics. Key products include the Chargemaster Toolkit and Bill Analyser solutions for charge integrity, the InSight Suite for value-cycle analytics and decision support, and the Sentry portfolio for 340B program management and pharmacy analytics, acquired in 2021.

The Craneware platform, also known as the Trisus value-cycle platform, provides a unified, cloud-based analytics environment that integrates financial, clinical and operational data to support better decision making. The company serves more than 1,500 health systems across the United States, representing a substantial penetration of the addressable hospital market.

Sector Backdrop

The US healthcare sector is one of the largest in the world, with annual expenditure exceeding USD 4 trillion. Hospitals and health systems operate under sustained financial pressure, driven by rising labour costs, Supply chain Inflation, evolving reimbursement frameworks, regulatory complexity and competitive pressure from non-traditional providers. Optimising revenue cycle, charge integrity, contract performance, drug acquisition costs and clinical operations is critical to provider profitability. Software-based analytics solutions that deliver actionable insights, automate routine processes and integrate disparate data sources are essential tools for navigating this complexity. The 340B Drug Pricing Program, which provides discounted drug pricing to eligible hospitals serving low-income or rural populations, is particularly complex to manage and has been the subject of regulatory and operational scrutiny, supporting demand for specialised software and analytics solutions. Across the broader provider market, the shift towards value-based care, increasing transparency expectations from payers and patients, and ongoing digital transformation initiatives all support sustained demand for healthcare software.

Investment Thesis

Several elements underpin our positive view on Craneware. First, the company operates in a structurally attractive market with sustained demand and high switching costs for software solutions deeply embedded in hospital workflows. Second, recurring software revenue represents the substantial majority of total revenue, providing high Earnings visibility and quality. Third, customer retention rates are consistently very high, reflecting the mission-critical nature of the software and the strength of customer relationships. Fourth, the Sentry acquisition has significantly expanded the addressable market, broadened the customer base and created cross-sell opportunities across both legacy Craneware and Sentry customer bases. Fifth, the Trisus cloud platform provides a unified architecture that supports ongoing innovation, faster product development cycles and enhanced customer value. Sixth, the financial profile combines steady revenue growth, expanding adjusted EBITDA margins and strong cash generation, supporting both reinvestment and progressive dividends. Finally, the valuation embeds limited Credit for the cross-sell potential and continued operational momentum.

Growth Drivers

Several specific growth drivers reinforce the medium-term outlook. The integration of the Sentry product portfolio with the legacy Craneware solutions, combined with cross-sell to existing customers, is expected to drive expansion of average contract values. Migration of customers onto the Trisus cloud platform supports both higher recurring revenue and enhanced customer engagement. New product innovation, including value-based care analytics, Machine Learning-enabled insights, predictive analytics, drug acquisition cost optimisation and operational benchmarking, broadens the value proposition to existing customers and attracts new ones. Expansion of the customer base, particularly within smaller and mid-sized hospital systems, provides incremental revenue growth. The 340B program remains a critical focus, with ongoing regulatory and operational complexity supporting demand for specialised software. The combination of expansion within the existing customer base and new customer acquisition supports a multi-year growth runway.

Financial Performance

Craneware has delivered a long history of consistent revenue growth, strong cash generation and progressive Dividend payments. Following the Sentry acquisition, reported revenues have stepped up significantly and the company is now a substantially larger business than pre-acquisition. Annual recurring revenue, the metric that best reflects the underlying durability of the business, has continued to grow strongly. Adjusted EBITDA margins are in the high 20s to low 30s range, reflecting the high-Margin nature of established software with strong customer retention. Free Cash Flow conversion is strong, supporting both reinvestment in product development and a progressive dividend policy. Net Debt taken on for the Sentry acquisition is being steadily reduced from Operating Cash Flow, with the company's Leverage profile expected to return to historical conservative levels over the medium term.

The financial framework reflects multiple supportive metrics. Customer retention rates consistently exceed 95 percent, providing exceptional revenue visibility. Net revenue retention, which captures both retention and expansion within existing customers, has been increasing as cross-sell of the integrated portfolio gains traction. The mix shift from perpetual licence and services revenue towards SaaS subscription revenue has been improving margins, predictability and customer engagement. Total contract value across new bookings has been growing alongside the average customer relationship size. Together, these metrics provide a strong foundation for continued financial performance and reinforce confidence in the medium-term growth and margin trajectory.

US Healthcare Provider Trends

The US hospital sector continues to navigate complex operational and financial pressures. Labour shortages, particularly in nursing and skilled clinical roles, have driven wage inflation and contract labour usage. Supply chain costs, including pharmaceuticals, medical devices and supplies, have been elevated. Payer mix continues to shift, with growing Medicare Advantage penetration and evolving commercial insurance contracts requiring more sophisticated revenue cycle management. Regulatory complexity, including ongoing changes to the 340B program, price transparency requirements and value-based care frameworks, increases the demand for specialised software solutions. Across these dynamics, hospitals are investing in analytics, automation and decision support tools to identify efficiency opportunities, prevent revenue leakage and optimise drug acquisition costs. Craneware is exceptionally well positioned to serve these needs and continues to evolve its platform to address emerging customer requirements.

Product Innovation and Platform Outlook

Continued investment in product innovation underpins the long-term competitive position. The Trisus cloud platform provides a foundation for delivering integrated analytics across multiple operational and financial dimensions. New modules covering value-based care contract performance, denials management, contract optimisation, drug acquisition analytics, pharmacy spend management and operational benchmarking expand the customer value proposition. Application of machine learning and predictive analytics to charge integrity, denial prevention and contract performance provides differentiated value. Integration with electronic health record systems, financial systems and supply chain platforms supports seamless customer experience. As the platform continues to evolve, the company's ability to deliver compounding value to existing customers strengthens both retention and expansion.

Commercialisation Outlook

Craneware commercialises its solutions through a direct sales force complemented by customer success teams that ensure ongoing value delivery and identify expansion opportunities. The customer base spans both standalone hospitals and large integrated delivery networks, with sales cycles that vary by product and customer size. The Sentry acquisition expanded the customer base into pharmacy-focused use cases, particularly around the 340B program, providing access to a complementary buyer set within hospital systems. Customer success initiatives, Training programmes, user conferences and online resources support adoption, retention and expansion. Partnership relationships with consulting firms, technology partners and industry associations broaden market reach.

Dividend and Capital Returns

Craneware maintains a progressive dividend policy, with the distribution paid in US dollars to align with the company's revenue base. The dividend has grown steadily over many years and provides a meaningful contribution to total returns. Capital allocation priorities are reinvestment in product innovation, debt reduction following the Sentry acquisition, progressive dividend growth and selective bolt-on M&A. As leverage continues to moderate and free cash flow expands, scope for additional capital returns may emerge over time.

Valuation Perspective

Craneware trades on a valuation that reflects its high-quality recurring revenue, strong margins and growth profile, but in our view does not fully capture the cross-sell potential post-Sentry, the continued expansion of the Trisus platform or the ongoing margin expansion opportunity. Comparison with US healthcare technology peers suggests scope for re-rating as the company demonstrates further successful execution. Discounted cash flow analysis with conservative growth and margin assumptions points to meaningful upside from current levels. Combined with a progressive dividend and strong cash generation, total return potential is attractive.

Key Risks

Risks include execution of the Sentry integration and the broader cross-sell programme; potential changes to the 340B program that could affect customer demand for related software; competitive intensity in healthcare analytics and revenue cycle management; macroeconomic conditions affecting hospital IT spending; foreign exchange exposure given the dollar revenue base and sterling reporting currency; and the cyclical nature of hospital procurement decisions. Cybersecurity, data privacy and customer concentration are additional considerations relevant to enterprise software businesses. Integration risk and management bandwidth following a large acquisition also need monitoring.

Sustainability and ESG

Craneware's mission of helping healthcare providers operate more efficiently and deliver better outcomes aligns with broader healthcare system goals. The company emphasises strong governance, ethical compliance and stakeholder engagement. Environmental footprint of a software company is relatively modest but is being managed through energy efficiency, sustainable office operations and cloud infrastructure choices. Workforce diversity, talent development and community engagement support broader sustainability positioning.

Cross-Sell Opportunity and Trisus Platform

The Sentry acquisition created a meaningful cross-sell opportunity that is still in its early innings. Legacy Craneware customers, primarily focused on revenue cycle and charge integrity, can benefit from Sentry's 340B and pharmacy analytics solutions. Legacy Sentry customers, primarily focused on pharmacy and 340B program management, can benefit from Craneware's broader revenue cycle, charge integrity and value-based care solutions. The integration of both portfolios within the Trisus cloud platform supports a unified user experience and integrated Data Analytics that creates value beyond what either portfolio could deliver in isolation. Customer success teams are actively identifying and pursuing cross-sell opportunities, and the early results have been encouraging. As cross-sell penetration deepens, average customer contract values are expected to grow, supporting both revenue growth and Operating Leverage.

The Trisus platform itself represents a longer-term strategic asset. By providing a unified, cloud-based analytics environment that ingests data from multiple hospital systems, the platform enables Craneware to deliver new modules, applications and insights more efficiently than legacy on-premises software. As new use cases emerge in areas such as denials management, contract optimisation, drug acquisition cost analysis and value-based care, Trisus provides the foundation for rapid product development and deployment. The platform also supports the application of machine learning and artificial intelligence techniques, which are increasingly important to delivering predictive insights and automation in healthcare operations.

Conclusion: Why We Rate Craneware a Buy

Craneware PLC offers an attractive combination of high-quality recurring revenue, strong margins, structural demand for healthcare cost management software and meaningful cross-sell potential following the Sentry acquisition. With a proven business model, strong customer retention and a clear pathway for continued operational and financial improvement, the medium-term outlook is compelling. The valuation provides a reasonable entry point and continued execution should support a re-rating. We therefore rate Craneware PLC a Buy. The combination of high quality earnings, recurring revenue, expanding addressable market and meaningful cross-sell opportunity make the shares a high-conviction holding for investors seeking exposure to the structural growth of US healthcare technology.